Semaglutide
5 mg
Tirzepatide
Price range: $109.00 through $219.00
Research Use Only – Not for Human Consumption
Subcutaneous Injection
Lyophilized Powder
Product Information
This product is for Research Use Only (RUO)
It is not for human consumption. Use only in a laboratory setting by qualified personnel. The FDA has not evaluated this product for safety or efficacy. Any other use is strictly prohibited.
Tirzepatide Specifications
A synthetic 39-residue peptide built on the GIP backbone that engages both the GIP and the GLP-1 receptor, carrying a C20 fatty diacid chain associated with extended albumin binding.
Chemical Properties and Registry Information
| Property | Value |
| Name and synonyms | Tirzepatide, LY3298176, dual GIP/GLP-1 receptor agonist |
| Material category | Synthetic dual incretin receptor agonist peptide |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser (39 residues, C-terminal amide) |
| Molecular formula | C225H348N48O68 |
| Average molecular mass | 4813.45 g/mol |
| CAS Registry Number | 2023788-19-2 |
| PubChem CID | CID 156588324 |
| Structural features | Built on the glucose-dependent insulinotropic polypeptide (GIP) backbone. 2-aminoisobutyric acid (Aib) at positions 2 and 13 resists dipeptidyl peptidase-4 cleavage. Lys20 is acylated through a gamma-Glu-(AEEA)2 linker with eicosanedioic acid, a C20 fatty diacid associated with albumin binding. The C-terminus is amidated. |
| Appearance | White to off-white lyophilized powder in sterile glass vial |
| Solubility | Soluble in water |
| Physical form | Catalogue vial; exact salt/counter-ion and excipients are batch-specific and must be verified in the CoA and SDS. |
Note: Registry values apply only to the specific molecular entity, sequence, termini, and material form. Batch records take precedence over family-level literature identifiers.
Research Background and Published Evidence
Published research
Tirzepatide is used in incretin receptor pharmacology, where the feature most often examined is its activity at the GIP receptor relative to the GLP-1 receptor, and in comparative work against single-receptor GLP-1 agonists. Its discovery and in-vitro receptor characterisation were first reported by Coskun et al. [2]; large clinical programmes have since been published under the SURPASS and SURMOUNT names [3,4].
Current scientific understanding
Receptor and clinical publications describe defined study systems and populations and do not establish safety, efficacy, or suitability for this catalogue batch. Regulatory classification and permitted supply vary by jurisdiction.
Technical Comparison
| Aspect | This catalogue material | Comparator |
| Identity | Catalogue tirzepatide material, subject to exact-form batch confirmation | Exact tirzepatide reference standard |
| Structural distinction | Salt, counter-ion, residual solvent and nominal peptide content remain batch-specific | Defined 39-residue acylated peptide without formulation excipients |
| Analytical implication | Confirm identity, acylation and net peptide content against a matching standard and CoA | Reference formula, mass, CAS and CID apply only to the matching free peptide |
Quality and Testing
Quality information is batch- and presentation-specific. Use only the report linked to the exact size and lot. A report listed for another size, lot, or similarly named material must not be treated as evidence for this product.
Chromatographic area purity, identity, net peptide or analyte content, water or counter-ion content, sterility, endotoxin, and elemental impurities are different measurements. One result does not establish the others. Only tests supported by a visible, matching report should be regarded as available.
Laboratory Handling and Storage
Store and handle only under the conditions stated on the product label, batch CoA, and SDS. Keep the container secured, correctly identified, and protected from contamination. Do not infer storage, solvent compatibility, or stability from a related compound.
Laboratory preparation, analytical-method selection, risk assessment, personal protective equipment, and waste disposal should follow the applicable SDS and the institution’s approved procedures.
Regulatory and Legal Status
Research-use notice: This material is supplied exclusively by Alma Research Labs for laboratory research by qualified professionals and is not intended for human or veterinary use. Purchasers are responsible for compliance with applicable local requirements.
Sources and References
PubChem. Tirzepatide, CID 156588324.
Coskun et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist: from discovery to clinical proof of concept. Molecular Metabolism (2018).
Frias et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine (2021).
Jastreboff et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine (2022).
Related products
View All
This product is for Research Use Only (RUO)